CLINICAL TRIALS PROFILE FOR ZANAMIVIR
✉ Email this page to a colleague
All Clinical Trials for ZANAMIVIR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00540501 ↗ | A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects | Withdrawn | GlaxoSmithKline | Phase 1 | 2007-10-01 | This study is a 4 period study to see if there is any interaction between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects |
| NCT00784784 ↗ | Zanamivir Versus Trivalent Split Virus Influenza Vaccine | Completed | GlaxoSmithKline | Phase 3 | 2008-11-01 | This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers. |
| NCT00784784 ↗ | Zanamivir Versus Trivalent Split Virus Influenza Vaccine | Completed | Mount Sinai Hospital, Canada | Phase 3 | 2008-11-01 | This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers. |
| NCT00799760 ↗ | Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir | Terminated | GlaxoSmithKline | Phase 3 | 2008-12-01 | In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.Two antivirals are available for the treatment oseltamivir and zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will be investigated by a randomized, placebo controlled, double blind study in France, during the next winter season . This study will be conducted in 300 centres of primary care with 900 adults with a virologically suspected influenza A infection. Individuals will be randomized to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo +zanamivir.The primary judgment criteria will be the proportion of patients with negative RT PCR negative in nasal secretions at Day 2. |
| NCT00799760 ↗ | Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir | Terminated | Hoffmann-La Roche | Phase 3 | 2008-12-01 | In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.Two antivirals are available for the treatment oseltamivir and zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will be investigated by a randomized, placebo controlled, double blind study in France, during the next winter season . This study will be conducted in 300 centres of primary care with 900 adults with a virologically suspected influenza A infection. Individuals will be randomized to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo +zanamivir.The primary judgment criteria will be the proportion of patients with negative RT PCR negative in nasal secretions at Day 2. |
| NCT00799760 ↗ | Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir | Terminated | Assistance Publique - Hôpitaux de Paris | Phase 3 | 2008-12-01 | In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.Two antivirals are available for the treatment oseltamivir and zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will be investigated by a randomized, placebo controlled, double blind study in France, during the next winter season . This study will be conducted in 300 centres of primary care with 900 adults with a virologically suspected influenza A infection. Individuals will be randomized to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo +zanamivir.The primary judgment criteria will be the proportion of patients with negative RT PCR negative in nasal secretions at Day 2. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZANAMIVIR
Condition Name
Clinical Trial Locations for ZANAMIVIR
Trials by Country
Clinical Trial Progress for ZANAMIVIR
Clinical Trial Phase
Clinical Trial Sponsors for ZANAMIVIR
Sponsor Name
